FLORENCE, Italy--(BUSINESS WIRE)--Today at the WUWHS Congress in Florence, the WUWHS Consensus Document “Role of dressings in pressure ulcer prevention” was first presented. As well as highlighting the patient-related and economic benefits of using polyurethane foam dressings in PU prevention, the authors of the document present a guide for clinicians on the appropriate use of dressings, and emphasise the need to consider them as a complement to standard PU prevention.
Pressure ulcers are localised injuries to the skin and/or underlying soft tissue that usually occur as a result of pressure in combination with three other elements – shear, friction and microclimate (temperature and moisture).[ii] They are a challenging problem and have a significant impact on patient health and quality of life. Pressure ulcer prevalence rates have been reported to be as high as 29.9 percent in nursing homes and 23 percent in hospitals throughout Europe and North America,[iii] and in the USA alone, pressure ulcers cost the hospital sector an estimated USD 11 billion per year.
“Recognition of the huge economic, health-related and social burden of PUs has resulted in considerable efforts to reduce their occurrence. Despite this, they still occur. It is our hope that the WUWHS consensus document will help clinicians and health care budget holders understand the role of dressings in PU prevention, as well as which dressings may protect against PU development and which patients may benefit.” – Professor Nick Santamaria, Chair, Core Expert Working Group for the WUWHS consensus document, and Professor of Nursing Research, Translational Research, University of Melbourne and Royal Melbourne Hospital, Australia.
Of the 23 clinical studies reviewed in the WUWHS consensus document, the majority showed significant decreases in PU occurrence following the use of preventive dressings. A substantial proportion of the scientific and clinical evidence supporting the use of prophylactic dressings relates specifically to multi-layer polyurethane foam dressings with Safetac® (Mepilex® Border Sacrum and Mepilex® Border Heel) from Mölnlycke Health Care. The document further confirms that dressings should be applied to patients as soon as they have been identified as being at high risk of developing PUs.
Dressings differ in quality and construction. It is therefore important to select preventive dressings that have been proven to be effective in high-quality scientific and clinical studies. According to the WUWHS consensus document, dressings must mitigate the effects of the four extrinsic factors that contribute to pressure injury: pressure, shear, friction and microclimate. Understanding how dressing materials and construction affect the four factors helps to establish the ideal properties of a dressing for prevention. Clinicians should also be confident that both deep soft tissue deformations as well as superficial injuries are addressed when selecting preventive dressings.
“Pressure ulcer is the most frequent type of expensive, avoidable side-effect of care. The WUWHS consensus document provides important insight from leading experts in the field and reinforces Mölnlycke Health Care’s strategic focus on PU prevention.” - Richard Twomey, CEO of Mölnlycke Health Care.
To download the WUWHS Consensus document – Role of dressings in pressure ulcer prevention, please visit Mölnlycke Health Care Pressure ulcer prevention website. (http://pup.molnlycke.com/)
[i] World Union of Wound Healing Societies. Consensus document. Role of dressings in pressure ulcer prevention. Wounds International, 2016.
[ii] National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and treatment of pressure ulcers: clinical practice guideline. In: Haesler, E. (ed). Cambridge Media, 2014.
[iii] Demarre, L., Van Lancker, A., Van Hecke, A., Verhaeghe, S., Grypdonck, M., Lemey, J., Annemans, L., Beeckman, D. The cost of prevention and treatment of pressure ulcers: a systematic review. International Journal of Nursing Studies 2015; http://dx.doi.org/10.1016/j.jnurstu.2015.06.006
Notes for the editors:
Mölnlycke Health Care
Mölnlycke Health Care is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery. Our products and solutions provide value for money supported by clinical and health economic evidence.
Mölnlycke Health Care employs around 7,500 people and is owned by Investor AB. The company headquarters are in Gothenburg, Sweden and we operate in 90 countries worldwide. For more information, please visit www.molnlycke.com.
The Mölnlycke Health Care, Safetac® and Mepilex® trademarks are registered globally to one or more of the Mölnlycke Health Care Group of Companies.
This information was brought to you by Cision http://news.cision.com